StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR – Free Report) in a research report sent to investors on Thursday. The firm issued a sell rating on the stock.
InspireMD Price Performance
Shares of NYSE:NSPR opened at $2.50 on Thursday. The stock’s 50-day moving average is $2.38 and its 200 day moving average is $2.50. The company has a market cap of $62.21 million, a PE ratio of -3.28 and a beta of 0.95. InspireMD has a 1 year low of $1.81 and a 1 year high of $3.85.
InspireMD (NYSE:NSPR – Get Free Report) last posted its earnings results on Tuesday, May 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.06). The business had revenue of $1.51 million for the quarter, compared to analysts’ expectations of $1.38 million. InspireMD had a negative net margin of 350.35% and a negative return on equity of 55.12%. During the same period last year, the firm posted ($0.53) earnings per share. Analysts expect that InspireMD will post -0.82 EPS for the current fiscal year.
Institutional Trading of InspireMD
About InspireMD
InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.
Read More
- Five stocks we like better than InspireMD
- How to Calculate Options Profits
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- MarketBeat Week in Review – 6/24 – 6/28
- Top Stocks Investing in 5G Technology
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.